Svizera Labs Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Svizera Labs Private Limited Pharmaceutical Export Portfolio Dataset — 5 Products, $13.7M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Svizera Labs Private Limited — Pharmaceutical Exporter Profile (2026) | 5 Products, $13.7M Trade | TransData Nexus

Svizera Labs Private Limited

Indian Pharmaceutical Exporter · Tuberculosis Medications Specialist · $13.7M Total Trade · DGFT Verified

Svizera Labs Private Limited is an Indian pharmaceutical exporter with a total trade value of $13.7M across 5 products in 3 therapeutic categories. Based on 273 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Rifampicin ($3.9M), Isoniazid ($3.8M), Ethambutol ($2.3M).

Svizera Labs Private Limited — Export Portfolio & Destination Treemap

Svizera Labs Private Limited pharmaceutical export portfolio — 5 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is Svizera Labs Private Limited? — Company Overview & Market Position

Svizera Labs Private Limited, established on April 17, 1997, is a private pharmaceutical company headquartered in Thane, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U74999MH1997PTC107389. It operates as a non-government entity, classified as a private company limited by shares. The authorized share capital is ₹5.00 crore, with a paid-up capital of ₹2.80 crore. As of the latest available data, the company employs approximately 60 professionals. Svizera Labs specializes in the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's registered office is located at Plot No D-16/6, TTC-MIDC Industrial Area, Turbhe, Thane, Maharashtra, 400703.

What Does Svizera Labs Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Rifampicin$3.9M 2Isoniazid$3.8M

Product Portfolio — Top 5 by Export Value

Svizera Labs Private Limited exports 5 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Rifampicin	Advanced Antibiotics	$3.9M	77	0.3%	5
2	Isoniazid	Tuberculosis Medications	$3.8M	76	0.2%	5
3	Ethambutol	Tuberculosis Medications	$2.3M	46	0.2%	7
4	Pyrazinamide	Tuberculosis Medications	$1.9M	39	0.2%	5
5	Strip	Medical Devices & Diagnostics	$1.8M	35	0.9%	5

Svizera Labs Private Limited exports 5 pharmaceutical products across 3 therapeutic categories with a total export value of $13.7M. The top category is Tuberculosis Medications (59.0% of portfolio), followed by Advanced Antibiotics (28.2%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Svizera Labs Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Svizera Labs operates manufacturing facilities in the TTC-MIDC Industrial Area, Turbhe, Thane, Maharashtra. The plant specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Specific details regarding production capacities and certifications are not publicly disclosed. The company's focus on quality manufacturing aligns with its export activities, particularly in the tuberculosis medications segment.

3Key Leadership

The leadership team at Svizera Labs Private Limited comprises:

Maneesh Ramakant Sapte – Director, appointed on November 13, 2000.
Vinay Ramakant Sapte – Director, appointed on April 1, 2002.
Rashmi Vinay Sapte – Director, appointed on April 9, 1999.
Pareshkumar Pravinchandra Upadhyay – Director, appointed on November 28, 2019.

These individuals collectively oversee the strategic direction and operations of the company.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Svizera Labs Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Svizera Labs Private Limited's export activities are primarily focused on finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's export data indicates a total export value of $13.7 million USD across 273 shipments, with a portfolio concentration of 100% in its top five products. The top five products exported are Rifampicin ($3.9M), Isoniazid ($3.8M), Ethambutol ($2.3M), Pyrazinamide ($1.9M), and Strip ($1.8M). These products are primarily categorized under tuberculosis medications (59.0%), advanced antibiotics (28.2%), and medical devices & diagnostics (12.8%). The company's export data does not specify its presence in regulated markets such as the US, EU, UK, Australia, or Japan. Without detailed regulatory filings, approvals, or market access status, a comprehensive analysis of Svizera Labs' presence in these markets cannot be provided.

2Emerging Markets

Svizera Labs Private Limited's export data indicates a significant focus on tuberculosis medications, which are critical in emerging markets, particularly in regions with high TB prevalence. The company's export portfolio includes Rifampicin, Isoniazid, Ethambutol, and Pyrazinamide, all essential components in TB treatment regimens. While the export data does not specify the exact destinations of these products, the emphasis on TB medications suggests potential penetration into emerging markets in Africa, Latin America, and Southeast Asia. The World Health Organization (WHO) prequalification of these products would facilitate access to these markets, ensuring compliance with international quality standards. However, without specific information on WHO prequalification status, a detailed assessment cannot be provided.

Svizera Labs Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

The export data provided does not include specific information regarding Svizera Labs Private Limited's interactions with the U.S. Food and Drug Administration (FDA). Without details on FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or inspection history, a comprehensive assessment of the company's FDA status cannot be conducted. The absence of this information limits the ability to evaluate the company's compliance with FDA regulations and its potential market access in the United States.

2WHO & EU GMP

The export data does not provide information on Svizera Labs Private Limited's compliance with World Health Organization (WHO) Good Manufacturing Practices (GMP) or European Union (EU) GMP standards. Without details on WHO prequalification or EU GMP certificates, it is challenging to assess the company's adherence to these international quality standards. Compliance with WHO and EU GMP is crucial for market access in various regions and for ensuring the safety and efficacy of pharmaceutical products.

3CDSCO & Indian Regulatory

Svizera Labs Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Svizera Labs Private Limited operates in the pharmaceutical export sector, focusing on finished formulations for tuberculosis and advanced antibiotics. The company's top five products—Rifampicin, Isoniazid, Ethambutol, Pyrazinamide, and Strip—are essential components in TB treatment regimens. The competitive landscape in this segment includes other pharmaceutical companies that manufacture and export similar products. However, without specific market share data and information on key competitors, a detailed head-to-head analysis cannot be conducted. The company's emphasis on high-quality manufacturing and a focused product portfolio may provide a competitive edge in addressing global health challenges related to tuberculosis.

2Key Differentiators

Svizera Labs Private Limited's key differentiators include its specialized focus on tuberculosis medications and advanced antibiotics, which are critical in global health initiatives. The company's export data indicates a significant presence in these therapeutic areas, suggesting expertise and a commitment to addressing pressing health concerns. Additionally, the company's emphasis on finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, aligns with global trends towards ready-to-use dosage forms. However, the lack of diversification in its product portfolio may limit its ability to cater to a broader range of therapeutic areas.

Buyer Due Diligence Brief — Evaluating Svizera Labs Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Svizera Labs Private Limited's export data indicates a total export value of $13.7 million USD across 273 shipments, with a portfolio concentration of 100% in its top five products. This suggests a consistent and focused approach to its export activities. The company's emphasis on high-quality manufacturing aligns with its export focus on critical medications for tuberculosis and advanced antibiotics. However, the lack of diversification in its product offerings may expose the company to risks associated with market fluctuations and regulatory changes affecting these specific product categories. A more diversified product portfolio could mitigate such risks and enhance the company's resilience in the global pharmaceutical market.

2Certifications to Verify

Importers should verify the following certifications to ensure compliance with international quality standards:

FDA Approval: Confirm that the products are approved by the U.S. Food and Drug Administration

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — Svizera Labs Private Limited

How many pharmaceutical products does Svizera Labs Private Limited export from India?

Svizera Labs Private Limited exports 5 pharmaceutical products across 3 therapeutic categories. The top exports are Rifampicin ($3.9M), Isoniazid ($3.8M), Ethambutol ($2.3M), Pyrazinamide ($1.9M), Strip ($1.8M). Total export value is $13.7M.

What is Svizera Labs Private Limited's total pharmaceutical export value?

Svizera Labs Private Limited's total pharmaceutical export value is $13.7M, based on 273 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Svizera Labs Private Limited cover?

Svizera Labs Private Limited exports across 3 therapeutic categories. The largest are Tuberculosis Medications (59.0%, 3 products), Advanced Antibiotics (28.2%, 1 products), Medical Devices & Diagnostics (12.8%, 1 products).

Get Full Svizera Labs Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.